Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth Large Group NRA Formulary Coverage | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    EmblemHealth Large Group NRA Preferred Formulary — Formulary ID - LG (Preferred Drug Formulary)

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the EmblemHealth Large Group NRA preferred drug formulary describing covered drugs, tiers, utilization management (e.g., prior authorization, step therapy, quantity limits), member services and how to use the formulary for plan members and providers.

    Policy Summary
    PayerEmblemHealth
    PolicyLarge Group NRA Preferred Formulary (Formulary ID - LG)
    Policy CodePolicy N/A
    Change TypeAnnual formulary update (no material changes noted)
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked 'PA' and ensure requests comply with listed quantity limits and specialty routing to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-01-01formulary effective/updated date
    PA, QL, ST, SPutilization management types listed
    LGformulary identifier
    877-793-6253member services phone
    ~150+drug listings shown

    Formulary Coverage and Utilization Controls

    Product-level coverage and utilization controls

    Formulary coverage entries indicate tiering and utilization controls for each product; coverage is product-specific as listed below.

    Formulary listing entries: Each drug entry includes product name, strength/formulation, Drug Tier, and Requirements/Limits (e.g., PA, QL, ACA, LA, SP). Coverage and utilization controls apply per listed entry.

    Extract contains only product-level listings and controls; no patient-level medical necessity criteria present.

    Formulary coverage with utilization controls

    Coverage is subject to drug-specific utilization management noted beside each product

    Formulary coverage indicators: Drugs assigned Drug Tier 1-3 are covered under the formulary with utilization controls; Tier and annotations determine member cost-share and requirement for prior authorization or specialty dispensing.

    Derived from tier and PA/QL/LA/SP annotations in the listing

    Policy Summary
    PayerEmblemHealth
    PolicyLarge Group NRA Preferred Formulary (Formulary ID - LG)
    Policy CodePolicy N/A
    Change TypeAnnual formulary update (no material changes noted)
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a drug is marked 'PA' and ensure requests comply with listed quantity limits and specialty routing to avoid claim denial.
    SourceLink
    On This Page
    Formulary Coverage and Utilization ControlsFormulary Listings and Coding / Code TablesPrior Authorization, Documentation, Step Therapy and Denial RisksQuantity Limits per ProductDispensing Channel and Site-of-Care DesignationsAbbreviations and Requirements/Limits FlagsStep Therapy Indicators and ApplicationFormulary Scope and Purpose

    Specialty/PA/QL conditions

    Coverage is tiered and often conditional; many specialty and biologic products require authorization and have quantity limits.

    Specialty biologics and CF modulators: Coverage for listed specialty biologics (e.g., FASENRA, NUCALA, XOLAIR, TEZSPIRE) and cystic fibrosis modulators (e.g., KALYDECO, TRIKAFTA, ORKAMBI, SYMDEKO) is provided only when LA/PA requirements are met and within specified QL limits.PA + QL as listed

    Prescribers must follow PA process; specialty channel often required

    Inhaled bronchodilators and corticosteroids

    Standard inhaled and systemic respiratory agents are covered with tiering and quantity limits.

    Inhalers and nebulized bronchodilators: Many common inhalers (albuterol, fluticasone-salmeterol, budesonide, etc.) are covered with specified QL (e.g., 1-3 inhalers/30 days or blister counts).QL as listed per product

    Tier affects member cost-sharing

    General formulary coverage conditions

    Coverage and utilization management for listed outpatient drugs

    Formulary coverage rules: Drugs listed include a Drug Tier and may have Requirements/Limits (PA, QL, SP, LA, ACA). Coverage and dispensing are contingent on meeting those requirements and adhering to quantity limits per specified time periods.

    Exact clinical criteria for PA not included in this segment; this is the formulary listing portion.

    The formulary includes a general disclaimer: presence on the formulary does not guarantee payment. Some drugs listed may not be paid for by all drug benefit plans and coverage is not guaranteed — members and providers must check the member's Certificate of Coverage or contact the plan for specific payment and copay details.

    Within the provided extract there is no explicit medical‑necessity exclusion language. Individual line items that show a blank or a dot for Requirements/Limits simply indicate no additional restrictions listed in this excerpt; explicit clinical exclusion statements are not included here.

    No explicit exclusion statements are present in these chunks — the excerpt consists of formulary drug listings with tier assignments and Requirements/Limits annotations (e.g., PA, QL, LA, SP) but does not contain standalone exclusion language.

    This extract does not show any product‑level exclusions. Formulary lines include Requirements/Limits flags and quantity limits for products, but no products are stated here as specifically excluded in the provided segments.

    No explicit exclusion conditions are provided in this segment; the material lists covered drugs, their tiers and utilization controls (PA, QL, SP, LA), but does not include clinical exclusion criteria or conditional exclusions in the shown lines.

    There are no items explicitly labeled 'Not Medically Necessary' in this extract. The entries present drug names, tiers and Requirements/Limits annotations but do not include NMN determinations in the provided text.

    The excerpt does not include any 'Not Medically Necessary' determinations. Drug listings in these chunks show tiers and occasional utilization flags but no NMN language is present.

    In this partial extract there are no 'Not Medically Necessary' (NMN) statements. The content is limited to formulary listings, tiers, and Requirements/Limits annotations (e.g., QL, PA, SP) without NMN rulings.

    Formulary Listings and Coding / Code Tables

    Formulary drug listings in excerptNDC|proprietary descriptionsCovered
    amoxicillin (trihydrate) tab 500 mg, 875 mgamoxicillin (trihydrate) tab 500 mg, 875 mg
    amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mgamoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mg
    cefadroxil tab 1 gmcefadroxil tab 1 gm
    azithromycin tab 250 mgazithromycin tab 250 mg (Zithromax z-pak)
    clarithromycin tab 250 mg, 500 mgclarithromycin tab 250 mg, 500 mg
    fidaxomicin tab 200 mg (Dificid)fidaxomicin tab 200 mg (Dificid)
    doxycycline hyclate cap 50 mg, 100 mgdoxycycline hyclate cap 50 mg, 100 mg
    ciprofloxacin hcl tab 250 mg, 500 mg, 750 mgciprofloxacin hcl tab 250 mg, 500 mg, 750 mg (Cipro)
    ARIKAYCE - amikacin sulfate liposome inhal susp 590 mg/8.4mlARIKAYCE - amikacin sulfate liposome inhal susp 590 mg/8.4ml
    TOBI PODHALER - tobramycin inhal cap 28 mgTOBI PODHALER - tobramycin inhal cap 28 mg
    1–10 of 16
    1/2
    Formulary drug entriesmixed
    famciclovir tab 125 mg, 250 mg, 500 mglisted drug with Drug Tier = 1
    GENVOYA - elvitegrav-cobic-emtricitab-tenofov af tab 150-150-200-10 mgDrug Tier = 2; QL (30 tablets/30 days)
    HARVONI - ledipasvir-sofosbuvir tab 45-200 mg, 90-400 mgDrug Tier = 2; PA, QL (28 tablets/28 days), SP
    INTELENCE - etravirine tab 25 mgDrug Tier = 2; QL (120 tablets/30 days)
    ISENTRESS - raltegravir potassium chew tab 25 mg, 100 mgDrug Tier = 2; QL (180 tablets/30 days)
    ISENTRESS - raltegravir potassium packet for susp 100 mgDrug Tier = 2; QL (60 packets/30 days)
    ISENTRESS - raltegravir potassium tab 400 mgDrug Tier = 2; QL (60 tablets/30 days)
    ISENTRESS HD - raltegravir potassium tab 600 mgDrug Tier = 2; QL (60 tablets/30 days)
    JULUCA - dolutegravir-rilpivirine tab 50-25 mgDrug Tier = 2; QL (30 tablets/30 days)
    KALETRA - lopinavir-ritonavir soln 400-100 mg/5mlDrug Tier = 2; QL (480 mls/30 days)
    1–10 of 23
    1/3
    Listed drugs (no billing codes provided in this segment)mixed
    No codes listed
    NDC/CPT/HCPCS not listed in this extractmixed
    No codes listed
    Formulary drug entries (partial)mixed
    OPFOLDAmiglustat (gaa deficiency) cap 65 mg
    ORFADINnitisinone susp 4 mg/ml
    ORILISSAelagolix sodium tab 150 mg / 200 mg
    OVIDRELchoriogonadotropin alfa soln prefilled syr 250 mcg/0.5ml
    PALYNZIQpegvaliase-pqpz subcutaneous soln pref syringe 2.5 mg/0.5ml, 10 mg/0.5ml, 20 mg/ml
    PHEBURANEsodium phenylbutyrate oral pellets 483 mg/gm
    PREGNYLchorionic gonadotropin for im inj 10000 unit
    RAVICTIglycerol phenylbutyrate liquid 1.1 gm/ml
    REVCOVIelapegademase-lvlr im soln 2.4 mg/1.5ml
    SKYTROFAlonapegsomatropin-tcgd for subcutaneous inj cartridges (multiple strengths)
    1–10 of 15
    1/2
    Cardiovascular agentsmixed
    DIGOXINdigoxin oral soln 0.05 mg/ml; digoxin tabs (various strengths)
    ISOSORBIDEisosorbide dinitrate/mononitrate products (various strengths)
    BETA BLOCKERSmultiple beta blocker agents (atenolol, carvedilol, metoprolol, propranolol, etc.)
    CALCIUM CHANNEL BLOCKERSamlodipine, diltiazem, nifedipine, verapamil (various strengths)
    Drugs listed (no explicit billing codes in excerpt)mixed
    N/AThis excerpt contains drug names and strengths but no CPT/HCPCS/ICD-10/NDC codes in the provided chunks.
    Cardiovascular agents - (additional)mixed
    Various ACE/ARB/diureticslisinopril, losartan, olmesartan, hydrochlorothiazide combinations and others listed without billing codes
    No procedure or diagnosis codes in this extractmixed
    No codes listed
    Selected ADHD agent NDC/descriptionsNDC
    atomoxetine hcl cap 10 mgatomoxetine hcl cap 10 mg (base equiv)
    atomoxetine hcl cap 18 mgatomoxetine hcl cap 18 mg (base equiv)
    atomoxetine hcl cap 25 mgatomoxetine hcl cap 25 mg (base equiv)
    atomoxetine hcl cap 40 mgatomoxetine hcl cap 40 mg (base equiv)
    atomoxetine hcl cap 60 mgatomoxetine hcl cap 60 mg (base equiv)
    atomoxetine hcl cap 80 mgatomoxetine hcl cap 80 mg (base equiv)
    atomoxetine hcl cap 100 mgatomoxetine hcl cap 100 mg (base equiv)
    Weight-management and wakefulness agentsNDC
    liraglutide (weight mngmt) 18 mg/3mlSaxenda soln pen-inj 18 mg/3ml (6 mg/ml)
    semaglutide (weight mngmt) pensWEGOVY soln auto-injector various strengths
    tirzepatide (weight mngmt) pensZEPBOUND soln auto-injector various strengths
    solriamfetol 75 mg, 150 mgSUNOSI tab 75 mg, 150 mg
    pitolisant 4.45 mg, 17.8 mgWAKIX tab 4.45 mg, 17.8 mg
    Formulary drug lines (no billing codes in this segment)mixed
    N/AThis segment is a drug formulary list and does not contain CPT/HCPCS/ICD-10 codes; it lists drug names, strengths, tiers, and requirements/limits.
    inv-25: Quantity limits examples
    Common tablet/month examplesQL examples shown in the formulary include 30 tablets/30 days and 28 tablets/28 days for antiviral agents
    High-count tablet examples120 tablets/30 days and 240 tablets/30 days appear for some oncology agents
    Annual/long-interval limitsSome products show limits expressed per year (e.g., 4-5 tablets/365 days for SUNLENCA)
    Liquid/packet examplesLarge-volume oral solutions and packets are limited (e.g., 960 mls/30 days for some antivirals; 120 packets/28 days for certain pediatric packs)
    Specialty kit/carton examplesSome therapies use kit/carton QLs (e.g., 1 carton/28 days for COMETRIQ kits)
    inv-26: Quantity Limit examples
    MENOSTAR (estradiol patch)QL: 4 patches/28 days
    FARXIGA (dapagliflozin)QL: 30 tablets/30 days
    MOUNJARO (tirzepatide)QL: 4 pens/28 days or 4 pens/180 days depending on strength
    OZEMPIC (semaglutide pen)QL: 1 pen/28 days or 3 pens/28 days depending on strength
    TRULICITY (dulaglutide)QL: 4 pens/28 days for certain strengths; 2 pens/28 days for higher strengths
    Generic estradiol topical bottlesQL: 5 bottles/93 days

    Prior Authorization, Documentation, Step Therapy and Denial Risks

    Prior Authorization

    Prior Authorization Required — general risk and program flags

    Many drugs listed in this formulary require prior authorization (PA) or other program-level controls before the plan will pay. Failure to obtain required PA, specialty routing (SP), limited availability (LA), or to comply with quantity limits (QL) or step-therapy (ST) edits may result in claim denial or non‑coverage.

    • Prior authorization (PA) is required for select agents and many specialty, antiviral, hepatitis C, antifungal, weight‑management, neurologic/respiratory, cystic fibrosis (CF) modulators, oncology and targeted therapies.
    • Drugs flagged with PA, LA, SP, QL, ACA, or ST in the formulary carry program-level controls — claims may be denied if these controls are not met.
    Prior Authorization

    Prior Authorization Required — select antiviral, antifungal and hepatitis C agents

    Specific high‑cost or specialty products listed in the formulary require PA and often have additional program flags (QL, SP, LA). Examples from the formulary include high‑cost antivirals and hepatitis C regimens (EPCLUSA, HARVONI, SOVALDI, VOSEVI, MAVYRET), antifungals (CRESEMBA, NOXAFIL, posaconazole, voriconazole), and select antivirals and combination HIV regimens.

    • Hepatitis C agents (EPCLUSA, HARVONI, SOVALDI, VOSEVI, MAVYRET) = PA + QL + SP in many presentations.
    • High‑cost antifungals (CRESEMBA, NOXAFIL, posaconazole, voriconazole) = PA.
    • Many antiviral/HIV combination products include QL and may require PA or ACA designations (e.g., Truvada, GENVOYA, STRIBILD).
    Prior Authorization

    Prior Authorization Required — antiviral, specialty and oncology agents

    Antiviral, specialty, and many oral specialty oncology agents require prior authorization and specialty routing; consult the formulary Requirements/Limits field and submit PA before dispensing to avoid denials.

    • Antivirals and HIV agents commonly show QL and PA designations (e.g., GENVOYA, ISENTRESS, SOVALDI).
    • Many oral oncology and targeted agents are LA, PA, QL, SP — see product line items (e.g., ALUNBRIG, ALECENSA, AKEEGA).
    • Failure to obtain PA or to route through specialty pharmacy (SP) can block payment.
    Prior Authorization

    Prior Authorization Required — specialty/oncology agents

    Many specialty oncology and targeted agents are documented with PA, LA, QL and SP flags. These designations mean prior approval, quantity limits, restricted dispensing channel, or limited availability apply; providers must follow these controls.

    • Examples include abiraterone (Zytiga), alectinib (ALECENSA), brigatinib (ALUNBRIG), avapritinib (AYVAKIT), erdafitinib (BALVERSA) — all require PA and are often SP/LA with QL.
    • Line‑item QL values (e.g., tablets/30 days, syringes/28 days) must be observed to avoid denial.
    Prior Authorization

    Prior Authorization Required — listed specialty/oncology and biologic agents

    Formulary items flagged with PA/QL/ST/LA/SP require provider action before fill. Commonly listed products with PA include many specialty biologics, CF modulators, and select branded drugs — obtain PA and ensure specialty routing or limits are met.

    • CF modulators and orphan/rare disease therapies (e.g., KALYDECO, ORKAMBI, OFEV) = LA, PA, QL, SP.
    • Oncology agents in the formulary are frequently LA/PA/QL/SP; confirm approval and the QL prior to dispensing.
    Prior Authorization

    Prior authorization required for select branded and GLP‑1 agents

    Some branded, commonly prescribed products also require prior authorization. Providers should verify PA needs for these drugs before prescribing or dispensing to members.

    • Examples include MYFEMBREE, MOUNJARO, TRULICITY, OZEMPIC which show PA and QL designations in the formulary.
    • Weight‑management and GLP‑1 agents (MOUNJARO, OZEMPIC, TRULICITY, RYBELSUS) frequently require PA and have QL per pen/pack/period.
    Prior Authorization

    PA and QL for weight‑management and select neurologic/respiratory agents

    Weight‑management and certain neurologic/respiratory agents carry combined PA and QL controls. Confirm PA and adhere to the listed quantity limits to prevent claim denials.

    • Weight‑management products (SAXENDA, WEGOVY, ZEPBOUND, ZEPOSIA entries for different classes) = PA + QL (pens or mL per days).
    • Neurologic agents and special respiratory biologics (e.g., FASENRA, TEZSPIRE) include PA and QL designations and may be routed as SP.
    Denial Risk

    Prior authorization risk — denial triggers

    Prior authorization risk: drugs that require PA may not be covered if approval is not obtained. Always check the formulary Requirements/Limits flags (PA, QL, LA, SP, ST, ACA) and obtain authorizations before dispensing.

    • Absence of PA at the time of claim submission is a common denial trigger.
    • Program flags (LA/PA/QL/SP/ST/ACA) are enforceable controls — noncompliance can result in non‑payment.
    Denial Risk

    Coverage controls and denial triggers

    Coverage controls and denial triggers: claims may be denied for not meeting program requirements (PA, exceeding QL, wrong dispensing channel if SP or LA applies, or failing ST sequence). Providers should confirm eligibility and authorization prior to dispensing.

    • Exceeding a listed QL (e.g., tablets/30 days, pens/28 days) can lead to denial.
    • Failure to follow step‑therapy (ST) where specified or to obtain prior authorization will commonly result in claim denial.
    Prior Authorization

    PA/QL/SP required for many specialty agents

    Many specialty products require PA, QL and SP routing. Obtain necessary approvals and dispense through the indicated channel to avoid denials and to meet clinical monitoring/handling requirements.

    • Specialty routing (SP) is required for many oncology, biologic, and rare disease products (line items include SP).
    • Adhere to QL values and PA requirements for specialty products when submitting claims.
    Denial Risk

    Failure to meet PA/QL/SP — potential denial

    Failure to meet PA, QL, SP or LA requirements may result in denial of payment. Ensure prior authorization is approved, quantity limits are respected, and specialty channel requirements are followed.

    • If PA is required and not obtained, the drug may not be covered.
    • Specialty and limited availability products must be dispensed through the approved channel to be eligible for coverage.
    Denial Risk

    Failure to meet PA/QL/LA triggers denial

    Some formulary entries note that lack of PA, SP, or LA will trigger denials or non‑coverage. Providers must confirm all program flags and approvals before prescribing or dispensing.

    • Absence of PA or exceeding QL/LA designations are explicit denial triggers in the formulary.
    • Confirm approvals for listed products such as MYFEMBREE, ORIAHNN, MOUNJARO, TRULICITY, OZEMPIC prior to fill.
    Prior Authorization

    Prior authorization required for specified products

    The formulary includes specific products with PA noted on their line items. Providers should verify PA status for these products and obtain approval before dispensing.

    • Selected examples with PA in the formulary: CRESEMBA, EPCLUSA, HARVONI, SOVALDI, VOSEVI, MOUNJARO, OZEMPIC, TRULICITY, MYFEMBREE.
    Denial Risk

    Quantity limits may trigger denial if exceeded

    Quantity limits (QL) are enforced across many drug categories. Claims exceeding the stated QL may be denied — review the product line‑item QL (units per days) and request exceptions if clinically indicated.

    • Example QLs: QL (28 tablets/28 days), QL (30 tablets/30 days), QL (4 pens/28 days), QL (6 syringes/28 days).
    • If medically necessary dosing exceeds QL, submit a PA request with supporting documentation or an exception request.
    Prior Authorization

    Authorization‑required drugs — provider action

    Drugs flagged PA/LA/SP require authorization steps. Providers must follow the formulary Requirements/Limits and submit PA requests per payer instructions before dispensing.

    • Authorization‑required examples: ACTHAR, GALAFOLD, GENOTROPIN, OPFOLDA and many enzyme/rare disease therapies.
    • LA indicates limited dispensing; SP indicates specialty channel — verify where the drug must be dispensed.
    Denial Risk

    Failure to meet listed requirements — follow Requirements/Limits field

    If the formulary line item indicates specified requirements (PA, LA, QL, SP), providers must meet those requirements or the request may be denied. Follow the Requirements/Limits field on each line item.

    • Examples: OPFOLDA, VOXZOGO, YORVIPATH and many others show LA, PA, QL and SP designations — confirm approvals and channel before dispensing.
    Denial Risk

    Quantity limit exceedance — submit documentation or exception request

    Some products have explicit quantity limit exceedance rules captured in the line items (e.g., VOXZOGO QL (30 vials/30 days)). Providers must request exceptions or PA with documentation if greater quantities are required.

    • When a QL is specified (vials, tablets, pens per period), claims exceeding that QL can be denied without an approved exception.
    • Submit clinical rationale and records to support requests to exceed QL.
    Prior Authorization

    Prior authorization and limits noted — check line items

    Prior authorization and limits are documented for many products; consult each line item for PA, QL, LA, SP flags and obtain pre‑approval as required.

    • Examples include REPATHA (PA, QL), QBRELIS (PA, QL), DIURIL (PA, QL) — ensure PA is in place and QL respected.
    Prior Authorization

    PA/LA/QL for CF therapies — documentation needed

    Cystic fibrosis (CF) therapies and other modulators are frequently designated LA/PA/QL/SP. Obtain PA and document dosing schedules and member genotype/clinical criteria as part of the authorization request.

    • CF modulators (KALYDECO, ORKAMBI) and alpha1‑proteinase products (GLASSIA) are SP and have QL; ensure PA and clinical documentation are submitted.
    • Provide genotype, prior therapy, and monitoring plan when requesting PA for CF therapies.
    Prior Authorization

    Prior authorization / program flags — interpret and act

    Program flags on the formulary (PA, ST, LA, SP, ACA, QL) indicate authorization, step‑therapy, limited availability or specialty routing are required. Providers should interpret these as enforceable controls and act accordingly.

    • PA/ST/LA/SP flags require prior action — verify plan‑specific requirements and obtain authorizations.
    • ACA indicates Affordable Care Act‑protected coverage for certain products when applicable.
    Prior Authorization

    Prior authorization required for select weight‑management and other agents

    PA is required for many weight‑management and other select agents listed. Confirm PA status and QL for these products before prescribing to avoid denials.

    • Weight‑management examples requiring PA: SAXENDA, WEGOVY, ZEPBOUND, ZEPOSIA (where applicable).
    • Some weight‑management agents also have QL per pens or mL per period — verify and obtain PA.
    Prior Authorization

    Prior authorization required for listed PA drugs

    For any drug line‑item that lists PA in Requirements/Limits, submit a prior authorization request. Requests without PA or required specialty handling may be denied.

    • Examples of PA‑listed drugs include REBIF TITRATION PACK, SODIUM OXYBATE, many biologics and specialty injected products.
    • If in doubt, contact EmblemHealth to confirm PA procedures and required documentation.
    Note

    Exceptions and alternative options

    Exceptions and alternative options: members can request an exception to a restriction or limit. Providers may request clinical exceptions and should discuss therapeutic alternatives with the member prior to submitting a PA/exception request.

    • Submit an exception request with supporting clinical documentation when the QL, PA, or channel requirement would prevent medically necessary therapy.
    • EmblemHealth can provide alternate covered drugs that may not require PA or have different limits.
    Documentation Required

    Quantity limit documentation — include dosing and rationale

    Quantity limit documentation: when QL is listed, include the member‑specific dosing and justification in the PA or exception request to support approval.

    • Include expected dose, duration, and rationale for doses exceeding the QL in the PA submission.
    • Provide prior therapy history if QL is related to tapering or titration schedules.
    Documentation Required

    Authorization documentation — what to submit

    Authorization documentation: prescribers must supply PA forms and any payer‑required clinical documents when requested. Specialty (SP) products often require additional paperwork and monitoring plans.

    • Provide diagnosis, prior treatments, relevant labs/genotype and treatment plan when requesting PA for specialty or oncology therapies.
    • Specialty pharmacy documentation and monitoring plans are commonly required for SP agents.
    Note

    Follow Requirements/Limits field — verify before dispensing

    Follow the Requirements/Limits field on each formulary line item. That field lists PA, QL, LA, SP, ST, ACA flags and any numeric limits — complying avoids denials.

    • Verify line‑item flags before prescribing or dispensing (PA, QL, LA, SP, ST, ACA).
    • If a drug shows LA or SP, confirm the correct dispensing channel or pharmacy network to avoid non‑coverage.
    Documentation Required

    Required documentation for PA/QL/SP

    Required documentation for PA/QL/SP: when PA or QL is invoked include clinical notes, prior medication trials, laboratory or genotype results, and a dosing schedule. Specialty products require evidence of monitoring and handling capability.

    • For oncology or specialty agents include staging, biomarker/genotype, prior lines of therapy, and treatment intent.
    • For CF and orphan disease drugs include genetic testing and specialist consultation notes.
    Documentation Required

    PA and QL documentation — include approvals and justifications

    PA and QL documentation: ensure the PA is submitted and that requested quantities do not exceed the stated QL unless an approved exception/PA to exceed is on file.

    • If PA is approved for a quantity above the QL, retain the approval documentation with the claim submission.
    • Document member‑specific justification when requesting quantities above line‑item QL.
    Documentation Required

    Documentation for PA/LA/SP — specialty routing and limited availability

    Documentation for PA/LA/SP: for medications with LA or requiring specialty dispensing, include justification for the dispensing location and documentation that the pharmacy meets specialty handling requirements.

    • When LA applies, indicate why the member must receive the drug from a specific pharmacy or supplier.
    • Specialty products (SP) often require distribution via contracted specialty pharmacies — include pharmacy acceptance/arrangement in the PA request.
    Documentation Required

    Supporting documentation for prior authorization

    Supporting documentation for prior authorization: provide drug‑specific clinical rationale, dosing schedule, prior therapies, and any monitoring plans. For rare/orphan and oncology drugs include specialty center involvement when applicable.

    • Include pathology, treatment history, and specialist notes for oncology PAs.
    • For enzyme replacement, genetic or rare disease therapies, include genetic testing and prior authorization from a specialist.
    Documentation Required

    Documentation required for PA and QL

    Documentation required for PA and QL: include the requested quantity, intended duration, clinical justification, prior medication history, and relevant lab/genetic results to support approval.

    • Follow payer guidance for clinical fields required on PA forms and attach supporting records where indicated.
    • If QL is measured in vials, pens, packets, or tablets per period, state the exact number and clinical reason for the requested supply.
    Documentation Required

    Documentation to support PA — dosing and monitoring

    Documentation to support PA: include dosing schedule, monitoring plan, and rationale in the PA submission. For biologics and specialty injectables, indicate who will administer and monitor therapy.

    • For injectables, state administration setting (clinic, home infusion) and monitoring arrangements.
    • Provide expected duration and plan for adverse event monitoring/reporting.
    Documentation Required

    Specialty product documentation — specialty routing and handling

    Specialty product documentation: SP products often require LA, PA, and QL designations be addressed in the submission. Use contracted specialty pharmacies and include specialty monitoring plans and handling instructions.

    • SP products (many oncology, biologic and orphan drugs) require specialty pharmacy dispensing and additional documentation.
    • Ensure the specialty pharmacy is authorized by EmblemHealth when routing SP claims.
    Documentation Required

    Quantity limits and specialty routing — adhere or document exception

    Quantity limits and specialty routing: adhere to QL and SP designations; exceeding QL or failing to route through specialty channels may lead to denial. When needed, request exceptions or PA with full supporting documentation.

    • If a therapy requires more than the QL or needs to be dispensed via SP, include that justification in the PA or exception request.
    • Contact EmblemHealth for guidance on approved specialty pharmacies and exception submission.
    Note

    Specialty/program requirements — interpret flags

    Specialty/program requirements: LA/PA/SP/ACA/ST flags indicate program‑level controls. Review these flags on each line item and follow payer procedures for PA, step‑therapy, limited availability, and specialty dispensing.

    • ST (step therapy) is present for select agents and must be followed where shown; some parts of the formulary do not specify step sequences explicitly.
    • ACA indicates certain products may be covered under Affordable Care Act protections when applicable.
    Step Therapy

    Step therapy — applicability and notes

    Step therapy notes: while many line items include PA/QL/LA/SP flags, explicit step‑therapy sequences are present only for select drugs (ST). Where ST is not specified in this segment, PA/QL/LA/SP remain the primary controls.

    • Some drugs include ST annotations (e.g., GRALISE, HORIZANT, specified psychiatric agents); other line items do not list a step sequence.
    • If ST applies, document prior failure or intolerance to required first‑line agents when requesting PA for later‑line therapy.

    Quantity Limits per Product

    inv-129: multiple antiviral, antiretroviral and antiviral combination products — QL varies by product
    ScopeMultiple antiviral, antiretroviral and antiviral-combination products are listed with product-specific QL values (varies by product)
    Tablet QLsExamples across antiviral class include 28 tablets/28 days, 30 tablets/30 days, 84 tablets/28 days
    Liquid/packet QLsSome agents have QL expressed as mls or packets (e.g., 960 mls/30 days; 28 packets/28 days)
    inv-130: ARIKAYCE — QL (28 vials/28 days)
    ARIKAYCE (amikacin liposome inhalation suspension 590 mg/8.4 ml)QL: 28 vials/28 days
    RequirementsListed with LA, PA, QL and SP where noted
    TierDrug Tier = 3 as listed
    inv-131: GENVOYA — 30 tablets
    GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide)QL: 30 tablets/30 days
    TierDrug Tier = 2
    Source noteListed in antiviral/antiretroviral section with QL (30 tablets/30 days)
    inv-132: HARVONI — 28 tablets
    HARVONI (ledipasvir-sofosbuvir)QL: 28 tablets/28 days
    AuthorizationRequirements include PA and SP for listed presentations
    Packaging notePellet pack presentations show QL as 28 packets/28 days
    inv-133: MAVYRET — 84 tablets
    MAVYRET (glecaprevir-pibrentasvir)QL: 84 tablets/28 days
    AuthorizationRequirements include PA and SP for listed presentations
    Alternate packPellet pack example shows QL 140 packets/28 days for other presentations
    inv-134: SUNLENCA — 4-5 tablets
    SUNLENCA (lenacapavir) therapy packs/tabsQL: 4–5 tablets/365 days depending on pack
    RequirementsListed with LA and SP and QL as shown per pack
    Presentation noteTherapy-pack and single-tab listings carry the annual QL (365 days)
    inv-135: PAXLOVID — 11-30 tablets depending on pack
    PAXLOVID (nirmatrelvir + ritonavir pack)QL: 11–30 tablets/30 days depending on pack size
    Pack examples6x150 mg nirmatrelvir + 5x100 mg ritonavir pack = QL 11 tablets/30 days; larger packs show QL up to 20–30 tablets/30 days as listed
    TierDrug Tier = 2
    inv-136: abiraterone acetate examples — QL values provided in-line
    Abiraterone acetate examplesQL values for abiraterone acetate are provided inline for strengths (e.g., QL 120 tablets/30 days and QL 60 tablets/30 days)
    AuthorizationEntries show PA and SP where indicated
    Therapy classListed under antineoplastic agents with LA/PA/QL flags
    inv-137: CAPRELSA - vandetanib tab 100 mg — 60 tablets
    CAPRELSA 100 mg (vandetanib)QL: 60 tablets/30 days
    CAPRELSA 300 mg (vandetanib)QL: 30 tablets/30 days
    RequirementsListed with LA, PA, QL and SP
    inv-138: CAPRELSA - vandetanib tab 300 mg — 30 tablets
    CAPRELSA 300 mg (vandetanib)QL: 30 tablets/30 days
    RequirementsListed with LA, PA, QL and SP
    TierDrug Tier = 2
    inv-139: COMETRIQ - cabozantinib kit — 1 carton
    COMETRIQ (cabozantinib) kitQL: 1 carton/28 days
    RequirementsListed with LA, PA, QL and SP for kit presentations
    Packaging noteMultiple kit sizes are listed with the same carton QL
    inv-140: dasatinib 20 mg — 90 tablets
    dasatinib 20 mg (Sprycel)QL: 90 tablets/30 days
    Other strengthsHigher strengths have different QLs (e.g., 30 tablets/30 days for larger strengths)
    RequirementsPA and SP noted where applicable
    inv-141: everolimus examples — 30 tablets
    everolimus (Afinitor) examplesTypical QL entries for everolimus formulations include 30 tablets/30 days (other lines show 60 or 90 tablets/30 days per presentation)
    AuthorizationPA and SP indicated for many formulations
    Therapy noteDifferent formulations (dispersible, tablets) have specific QLs listed
    inv-142: LYNPARZA - olaparib — 120 tablets
    LYNPARZA (olaparib)QL: 120 tablets/30 days
    RequirementsListed with LA, PA, QL and SP
    Strengths100 mg and 150 mg tablet presentations noted
    inv-143: NERLYNX - neratinib — 180 tablets
    NERLYNX (neratinib)QL: 180 tablets/30 days
    RequirementsListed with LA, PA, QL and SP
    Therapy classOral oncology agent with specialty handling
    inv-144: LUMAKRAS - sotorasib — 240 tablets
    LUMAKRAS (sotorasib) examplesQL entries include 240 tablets/30 days and 120 tablets/30 days depending on strength
    RequirementsListed with LA, PA, QL and SP for strengths shown
    TierDrug Tier = 3 in examples
    inv-145: pazopanib hcl tab 200 mg — 120 tablets
    pazopanib HCl 200 mgQL: 120 tablets/30 days
    RequirementsListed with PA and SP
    Alternate strength400 mg strength listed with QL 60 tablets/30 days
    inv-146: VITRAKVI - larotrectinib oral soln — 300 mls
    VITRAKVI (larotrectinib) oral solutionQL: 300 mls/30 days
    RequirementsListed with LA, PA and SP
    Alternate presentationCapsule presentations have separate QLs (e.g., 180 capsules/30 days)
    inv-147: VENCLEXTA - venetoclax tab 100 mg — 180 tablets
    VENCLEXTA (venetoclax) 100 mgQL: 180 tablets/30 days
    Starter packStarter packs have separate QL entries (e.g., 1 pack/180 days)
    RequirementsLA, PA and SP noted for presentations
    inv-148: TRUQAP - capivasertib — 64 tablets
    TRUQAP (capivasertib) therapy packQL: 64 tablets/28 days
    RequirementsListed with LA, PA, QL and SP
    Pack detailTherapy pack and single-tablet listings reference same QL per pack
    inv-149: MENOSTAR patch — 4 patches; Generic estradiol topical bottles — 5 bottles/93 days
    MENOSTAR (estradiol patch 14 mcg/24hr)QL: 4 patches/28 days
    Generic estradiol topical bottlesQL: 5 bottles/93 days
    Coverage notePatches and many contraceptives listed with ACA/LA designations where applicable
    inv-150: Generic estradiol topical bottles — 5 bottles/93 days
    Generic estradiol topical bottlesQL: 5 bottles/93 days
    MENOSTAR patchQL: 4 patches/28 days
    Regulatory noteContraceptives and certain IUDs carry ACA designations in listings
    inv-151: FARXIGA (dapagliflozin) — 30 tablets
    FARXIGA (dapagliflozin)QL: 30 tablets/30 days
    TierDrug Tier = 2
    ContextListed with common antidiabetic agents and QL entries
    inv-152: MOUNJARO (tirzepatide) — 4 pens
    MOUNJARO (tirzepatide)QL: 4 pens per fill (4 pens/28 days or 4 pens/180 days depending on strength presentation)
    RequirementsListed with PA and strength-specific QL in formulary
    TierDrug Tier = 2
    inv-153: OZEMPIC (semaglutide pen) — 1 pen/28 days or 3 pens/28 days depending on strength
    OZEMPIC (semaglutide pen)QL: 1 pen/28 days or 3 pens/28 days depending on strength
    RequirementsListed with PA and QL per strength
    TierDrug Tier = 2
    inv-154: TRULICITY (dulaglutide) — 4 pens/28 days or 2 pens/28 days depending on strength
    TRULICITY (dulaglutide)QL: 4 pens/28 days for certain strengths; 2 pens/28 days for higher strengths
    RequirementsListed with PA where indicated
    TierDrug Tier = 2
    inv-156: Multiple insulins — 100 mls often listed
    Insulin QL (general)Standard quantity limit for many basal, rapid- and intermediate-acting insulins is 100 mls per 30 days
    Presentations coveredIncludes pens, cartridges and vials across brands (e.g., INSULIN GLARGINE-YFGN, SEMGLEE, TOUJEO, TRESIBA)
    Provider notePrescriptions should be dispensed consistent with the listed QL to avoid claim denial
    inv-157: GALAFOLD (migalastat) — 14 capsules
    GALAFOLD (migalastat)QL: 14 capsules/28 days
    RequirementsListed with LA, PA, QL and SP
    TierDrug Tier = 3
    inv-158: CRENESSITY (crinecerfont oral soln) — 120 mls
    CRENESSITY (crinecerfont) oral solutionQL: 120 mls/30 days
    RequirementsListed with LA, PA, QL and SP
    PresentationsCapsule and oral solution presentations each have specified QLs
    inv-159: KERENDIA (finerenone) — 30 tablets
    KERENDIA (finerenone)QL: 30 tablets/30 days
    RequirementsListed with QL and ST where indicated
    TierDrug Tier = 2
    inv-160: OPFOLDA (miglustat) — 8 capsules
    OPFOLDA (miglustat)QL: 8 capsules/28 days
    RequirementsListed with LA, PA, QL and SP
    Indication contextUsed for specific rare disease indications with specialty handling
    inv-162: ORILISSA 150 mg — 30 tablets; inv-163: ORILISSA 200 mg — 60 tablets
    ORILISSA 150 mgQL: 30 tablets/30 days
    ORILISSA 200 mgQL: 60 tablets/30 days
    RequirementsListed with PA and QL
    inv-164: OVIDREL — 2 syringes
    OVIDREL (choriogonadotropin alfa)QL: 2 syringes/30 days
    RequirementsListed with PA and QL and SP where indicated
    PresentationPrefilled syringe presentations specified
    inv-165: VOXZOGO — 30 vials
    VOXZOGO (vosoritide)QL: 30 vials/30 days
    RequirementsListed with LA, PA, QL and SP
    TierDrug Tier = 3
    inv-166: VYKAT XR 25 mg — 120 tablets; inv-167: VYKAT XR 75 mg — 210 tablets; inv-168: VYKAT XR 150 mg — 90 tablets
    VYKAT XR 25 mgQL: 120 tablets/30 days
    VYKAT XR 75 mgQL: 210 tablets/30 days
    VYKAT XR 150 mgQL: 90 tablets/30 days
    inv-169: TYMLOS — 1 pen; inv-170: TRYNGOLZA — 1 injection device
    TYMLOS (abaloparatide)QL: 1 pen (per fill)
    TRYNGOLZA (olezarsen)QL: 1 injection device/28 days
    RequirementsListed with LA/PA/QL and SP where applicable
    inv-171: QBRELIS — 1200 mls; inv-172: DIURIL — 1200 mls; inv-173: REPATHA — 6 syringes/pens
    QBRELIS (lisinopril oral solution)QL: 1200 mls/30 days
    DIURIL (chlorothiazide suspension)QL: 1200 mls/30 days
    REPATHA (evolocumab)QL: 6 syringes/pens (6 syringes/28 days)
    inv-174: ADVAIR HFA — 1 inhaler; inv-175: AIRSUPRA — 3 inhalers; inv-176: ANORO ELLIPTA — 60 blisters
    ADVAIR HFA (fluticasone-salmeterol)QL: 1 inhaler/30 days
    AIRSUPRA (albuterol-budesonide)QL: 3 inhalers/30 days
    ANORO ELLIPTAQL: 60 blisters/30 days
    inv-177: FASENRA PEN — 1 pen; inv-178: NUCALA pref syringe 40 mg — 1 syringe
    FASENRA PEN (benralizumab)QL: 1 pen/28 days
    NUCALA pref syringe 40 mgQL: 1 syringe/28 days (other presentations list 3 syringes/28 days)
    RequirementsLA/PA/QL and SP indicated for biologic injectables
    inv-179: CF modulators — QL varies (examples provided)
    CF modulators (examples)QL varies by product: examples include 60 tablets/30 days, 56 packets/28 days, 90 tablets/30 days
    RequirementsDesignated LA, PA, QL and SP for cystic fibrosis therapies
    Products citedKALYDECO, SYMDEKO, TRIKAFTA, ORKAMBI show differing QLs as listed
    inv-180: bupropion er 12hr 150 mg — 60 tablets; inv-181: bupropion er 24hr 150 mg (XL) — 90 tablets; inv-182: duloxetine 60 mg — 60 capsules
    bupropion ER 12hr 150 mgQL: 60 tablets/30 days
    bupropion ER 24hr (XL) 150 mgQL: 90 tablets/30 days
    duloxetine 60 mgQL: 60 capsules/30 days
    inv-183: venlafaxine er 37.5 mg — 180 capsules; inv-184: REXULTI — 30 tablets; inv-185: ZURZUVAE — 28 capsules
    venlafaxine ER 37.5 mgQL: 180 capsules/30 days
    REXULTI (brexpiprazole)QL: 30 tablets/30 days
    ZURZUVAE (zuranolone)QL: 28 capsules/365 days (other strengths have different annual limits)
    inv-186: tasimelteon (Hetlioz) — 30 capsules; inv-187: JORNAY PM — 30 capsules; inv-188: atomoxetine caps — 60/30 depending on strength
    tasimelteon (Hetlioz)QL: 30 capsules/30 days
    JORNAY PM (methylphenidate delayed ER)QL: 30 capsules/30 days
    atomoxetine capsulesQL: 60 capsules/30 days for lower strengths; 30 capsules/30 days for higher strengths
    inv-189: liraglutide (Saxenda) — 15 mls; inv-190: WEGOVY — 8 pens/180 days; inv-191: ZEPBOUND — 4 pens/180 or 4 pens/28 days
    liraglutide (Saxenda)QL: 15 mls/30 days
    WEGOVY (semaglutide)QL: 8 pens/180 days or 4 pens/28 days depending on strength
    ZEPBOUND (tirzepatide)QL: 4 pens/180 days for 2.5 mg; 4 pens/28 days for higher strengths
    inv-192: INGREZZA — 28/30; inv-193: REBIF TITRATION PACK — 1 kit; inv-194: SODIUM OXYBATE — 3 bottles
    INGREZZA (valbenazine)QL: 28 capsules/180 days (therapy pack) or 30 capsules/30 days (standard)
    REBIF TITRATION PACKQL: 1 kit/180 days
    SODIUM OXYBATEQL: 3 bottles/30 days
    inv-195: VUMERITY — 120 capsules; inv-196: XYWAV — 540 mls; inv-197: ZEPOSIA — 30 capsules
    VUMERITY (diroximel fumarate)QL: 120 capsules/30 days
    XYWAV (oxybat solution)QL: 540 mls/30 days
    ZEPOSIA (ozanimod)QL: 30 capsules/30 days
    inv-198: Adalimumab biosimilars — 1-2 pens/syringes/kits; inv-199: ARCALYST — 8 vials; inv-200: ENBREL — 4 syringes/28 days
    Adalimumab biosimilarsQL: 1–2 pens/syringes/kits per 28–180 days depending on presentation
    ARCALYST (rilonacept)QL: 8 vials/28 days
    ENBREL (etanercept)QL: 4 syringes/pens or 8 vials/28 days depending on presentation
    inv-201: OLUMIANT — 30 tablets; inv-202: RINVOQ — 30 tablets
    OLUMIANT (baricitinib)QL: 30 tablets/30 days
    RINVOQ (upadacitinib)QL: 30 tablets/30 days
    RequirementsBoth listed with LA/PA/QL and SP where applicable

    Dispensing Channel and Site-of-Care Designations

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Abbreviations and Requirements/Limits Flags

    inv-95: Tiers — Tier 1 = Generic; Tier 2 = Preferred brand; Tier 3 = Non-preferred brand
    Tier definitionsTier 1 = Generic; Tier 2 = Preferred brand; Tier 3 = Non-preferred brand
    ACA noteACA entries may be $0 cost-share preventive drugs for eligible members
    SourceFormulary tier definitions provided in the document header
    inv-96: Abbreviations — PA, QL, SP, ST, FF, LA explained
    PAPrior Authorization — plan requires approval before the drug is covered
    QLQuantity Limit — the plan limits the amount of drug covered within a specified time period
    SPSpecialty — drugs that may require special handling, monitoring, or specialty pharmacy dispensing
    inv-97: Formulary requirement abbreviations — mapping of PA/QL/SP/LA/ACA
    PAPrior Authorization — approval required before coverage is provided (shown next to product entries)
    QLQuantity Limit — numeric limit expressed as units per period (e.g., tablets/30 days, mls/30 days)
    SPSpecialty Pharmacy designation — indicates route/handling and specialty dispensing may be required
    inv-98: Requirements/Limits flags — short codes appended to entries (ACA, PA, QL, LA, SP)
    Flags used in listingsCommon short codes appended to entries include ACA, PA, QL, LA, SP
    ImpactThese flags indicate utilization management (e.g., PA or QL) or coverage designation (ACA)
    Provider actionFollow the Requirements/Limits field for each product when submitting claims
    inv-99: Abbreviations used in listings — PA, QL, SP, LA
    PAPrior Authorization — plan requires approval prior to coverage (listed as 'PA')
    QLQuantity Limit — maximum units allowed per time period (listed as 'QL')
    LALimited Access — indicates restricted distribution or site-of-care limitations (listed as 'LA')

    Step Therapy Indicators and Application

    Policy statementSupport
    Member may be required to try specified alternative drugs before coverage of the requested agent (step therapy).Some drugs are subject to step therapy (ST), requiring trial of specified alternative(s) before coverage — see formulary abbreviations and step therapy note.
    Examples where ST is applied are indicated on product lines; check Requirements/Limits flags for ‘ST’ or product-level entries.Source: Abbreviations definition and Step Therapy Requirement (ST) description in formulary legend.
    Program flagMeaning / effect on coverage
    LA — Limited AvailabilityMay restrict distribution to select pharmacies or sites; may indicate additional authorization or limited channel.
    PA — Prior AuthorizationRequires payer approval before the drug is covered; failure to obtain PA may result in non‑coverage.
    SP — SpecialtyDesignates specialty pharmacy handling; specialty routing and documentation typically required for dispensing.
    ACA — Affordable Care Act designationIndicates ACA preventive coverage implications for eligible products (e.g., many vaccines, contraceptives).
    Product examplesST applicability / annotation
    HARVONI (ledipasvir-sofosbuvir)Marked PA, QL and SP — step-management indicated where SP is noted; specialty program controls apply.
    MAVYRET (glecaprevir-pibrentasvir)Marked PA, QL and SP — step/program-level management applies under specialty designation.
    SOVALDI (sofosbuvir)Marked PA, QL and SP — step therapy/program routing applies where SP is indicated.
    PEGASYS (peginterferon alfa-2a)Marked PA and SP — specialty and prior authorization controls referenced; program-level steps may apply.
    VOSEVI (sofosbuvir-velpatasvir-voxilaprevir)Marked PA, QL and SP — specialty pathway indicates step/program controls for coverage.
    ProductFormulary flags / handling
    PALFORZIA (peanut allergen powder) — Initial and maintenance packsRequirements/Limits = ACA, LA, SP — limited availability and specialty pharmacy handling noted for starter/maintenance packs.
    PALFORZIA Level and Maintenance presentationsEach level entry includes ACA, LA, SP flags indicating restricted distribution and specialty management for dosing stages.
    LA interpretationPolicy note
    LA (Limited Availability)Document defines LA as limited availability; it may restrict where the drug can be obtained and imply additional authorization or channel requirements.
    Payer discretionThe brief notes LA may indicate prior authorization or step edits at the payer’s discretion; check product Requirements/Limits for specifics.
    Excerpt summaryImplication for step therapy sequencing
    Formulary segments primarily list PA and QL requirements rather than explicit step therapy sequences.This portion of the formulary does not specify step-by-step sequencing; clinicians must follow product-level flags (PA, QL, SP, LA) and payer policies for any ST rules.
    No explicit ST sequences in segmentProviders should refer to program-specific PA/ST documentation or contact EmblemHealth for required step details.
    Drug category / examplesControls present (PA / QL / ST)
    Antidiabetic and weight‑management agents (examples: MOUNJARO, OZEMPIC, RYBELSUS)Entries show PA and QL designations; explicit step sequencing is not listed in this excerpt.
    MOUNJARO — tirzepatideRequirements/Limits = PA, QL (4 pens/28 or 180 days) — subject to prior authorization and quantity limits.
    ProductST flag present
    KERENDIA (finerenone)Requirements/Limits = QL (30 tablets/30 days), ST — product line includes ST flag indicating step therapy may apply.
    Search resultNote
    No explicit step therapy sequences provided in these chunksChunks list utilization flags (LA/PA/QL/SP) but do not define multi-step treatment pathways.
    Search resultNote
    No explicit step-therapy sequences listed in this excerptManagement is indicated by LA/PA/QL/SP annotations; step sequencing not described here.
    Excerpt observationImplication
    No explicit step therapy sequences are described in these lines — tiering and QL determinations predominate.Coverage decisions primarily referenced to PA and QL; ST may be applied where 'ST' flag appears elsewhere in the formulary.
    Coverage labelMeaning
    ST — Step TherapyProducts labeled 'ST' require adherence to the formulary's step requirements prior to coverage of the listed drug.
    Examples of ST-marked productsFLUOXETINE DR, certain ODT risperidone presentations, GRALISE and HORIZANT entries are marked ST in the formulary extract.
    ProductST requirement
    GRALISE (gabapentin once-daily 900 mg)Requirements/Limits = QL (60 tablets/30 days), ST — step therapy required for coverage.
    HORIZANT (gabapentin enacarbil)Listed with QL and ST flags indicating step therapy applies prior to coverage.
    ObservationSupport
    Some specialty and high‑cost agents require PA and may be subject to step editsChunks show numerous specialty lines with LA, PA, QL and SP flags; step edits may be applied though not detailed in the extract.
    Examples: VYLEESI, WAINUA, XYWAV, ARCALYST entries show LA/PA/QL/SP; step editing may be part of program controls.Source lines indicate LA, PA, QL and SP for listed specialty products though step sequences are not specified.

    Formulary Scope and Purpose

    Background: The EmblemHealth formulary lists covered brand‑name and generic drugs and assigns them to tiers (Tier 1 = generic, Tier 2 = preferred brand, Tier 3 = non‑preferred brand). The formulary also indicates program and utilization controls — for example, Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), Specialty (SP) and Limited Access (LA) — alongside each product as applicable to guide coverage and dispensing.